Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in relapsed or refractory CLL
NCT01510756Phase 2Terminated
- Start
- Dec 2011
- Primary completion
- May 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in chronic lymphocytic leukemia (CLL). Primary endpoint: Overall Response Rate at 3 months. Started Dec 2011; status: terminated.
02
Drugs
sorafenib
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT01510756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01510756.